NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study. In the influenza mouse lethal infection model, animals treated with one of the optimized FluCide™ nanoviricide drug candidates survived beyond the stated full duration of study (21 days), and those treated with two additional drug candidates survived almost the full duration of the study. Animals in these three groups survived significantly longer (20.2 to 22.2 days) as compared to the animals treated with Oseltamivir (Tamiflu®; only 8.3 days).
The quick explanation of what NanoViricides is making: injectable cell decoys that trick viruses into attaching to them and destroying themselves as they would in the process of infecting living cells. To become resistant to such an attack, a virus would have to mutate in such a way that it could no longer infect living cells, an evolutionary dead end.
This study is purposefully designed to be 100% fatal within five days, and yet these mice survived the full three weeks of it. Just imagine what these drugs could potentially do for people and animals suffering from normal infections (or, better yet, how quickly outbreaks could be halted were these nanoparticles administered prophylactically).
As always, do your due diligence if this interests you. I'm long shares of NNVC and I am making no recommendation to buy nor to sell.